Clonal evolution in progressive CLL patients harboring subclonal TP53 aberrations treated with ibrutinib first-line
Latest Information Update: 05 Aug 2021
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacodynamics
- Acronyms CLOSE (PS-CLL-001)
Most Recent Events
- 05 Aug 2021 New trial record